undamentalytics Newsletter

Summit Therapeutics Inc. valuation and forecast

Explore the models for Summit Therapeutics Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Summit Therapeutics Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

17 analysts, Oct 2026
Buy1165%
Hold635%
Sell00%

Monthly trend

  1. Oct 202610617
  2. Sep 202610617
  3. Aug 20269717
  4. Jul 202695217

Counts of recommendations published by analysts covering Summit Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

SMMT valuation questions

How does Fundamentalytics value Summit Therapeutics Inc.?
We use the models that fit Summit Therapeutics Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Summit Therapeutics Inc.